Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L)
This study is ongoing, but not recruiting participants.
Sponsor:
University Hospitals of Cleveland
Collaborator:
Case Western Reserve University
Information provided by (Responsible Party):
Martha Sajatovic, University Hospitals of Cleveland
ClinicalTrials.gov Identifier:
NCT01152697
First received: June 24, 2010
Last updated: May 1, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%. Inadequate adherence is associated with poor outcomes such as relapse, homelessness, hospitalization, and increased health care costs. Studies have shown a direct correlation between non-adherence and rates of relapse in schizophrenia; on average, non-adherent patients have a risk of relapse that is 3.7 times greater than their adherent counterparts. A major obstacle to good outcomes in the maintenance treatment of patients with severe mental illness is difficulty with medication routines on an on-going basis. For this reason, long-acting injectable antipsychotic medication is a particularly attractive treatment option for populations with schizophrenia and schizoaffective disorder, although it is unlikely that medication treatment alone is likely to modify long-term attitudes and behaviors.
This prospective study is a pilot analysis of a combined approach which merges a psychosocial intervention to optimize treatment attitudes towards psychotropic medication (CAE) and long-acting injectable antipsychotic medication (L) in recently homeless individuals with schizophrenia or schizoaffective disorder who are known to have on-going difficulties with treatment non-adherence. It is expected that this combined approach (CAE-L) will improve illness outcomes among the most vulnerable of populations with schizophrenia or schizoaffective disorder.
| Condition | Intervention |
|---|---|
|
Patient Noncompliance |
Drug: haloperidol decanoate Drug: haloperidol Behavioral: Customized Adherence Enhancement |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Supportive Care |
| Official Title: | A Prospective Trial of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L) in Individuals With Schizophrenia or Schizoaffective Disorder at Risk for Treatment Non-adherence and for Homelessness |
Resource links provided by NLM:
Further study details as provided by University Hospitals of Cleveland:
Primary Outcome Measures:
- Change from baseline in days homeless out of the previous 6 months as measured at 25 weeks [ Time Frame: Baseline-25 weeks ] [ Designated as safety issue: No ]Subjects will be asked how many days they have been homeless
- Change from baseline in treatment adherence score as measured at 25 weeks [ Time Frame: Baseline-25 weeks ] [ Designated as safety issue: No ]A total treatment adherence score will calculated as a proportion of medications taken as reported from the participant, and evidenced by pill counts and documented medication injections.
- Change from baseline in adherence attitude score as measured by the Drug Attitude Inventory (DAI) at 25 weeks [ Time Frame: Baseline-25 weeks ] [ Designated as safety issue: No ]Ten item inventory taken by the participant with a Scale Range: 0-10
- Change from baseline in treatment adherence behavior score as measured by the Morisky Medication Rating Scale at 25 weeks [ Time Frame: Baseline-25 weeks ] [ Designated as safety issue: No ]Four item inventory taken by participant with Scale Range: 0-4
- Change from baseline in adherence attitude score as measured by the Attitude toward Medication Questionnaire (AMQ) at 25 weeks [ Time Frame: Baseline-25 weeks ] [ Designated as safety issue: No ]Nineteen item inventory taken by the participant with Scale Range:0-19
Secondary Outcome Measures:
- Frequency of health resource use in the past 3 months as measured at 12 months [ Time Frame: 9 months-12 months ] [ Designated as safety issue: No ]The frequency of health resource use will be measured through interview of the participant.
- Change in serious mental illness severity score as measured by the Brief Psychiatric Rating Scale (BPRS) at 25 weeks [ Time Frame: Baseline-25 weeks ] [ Designated as safety issue: No ]
The BPRS, developed by Overall and Gorham (1962), is a widely used, relatively brief scale that measures major psychotic and non-psychotic symptoms in individuals with SMI. The 18-item BPRS is well-validated and is perhaps the most researched instrument in psychiatry. Reliability coefficients are reported to be in the range of 0.56-0.87.
Scale Range: 18-126
- Change in global psychopathology as measured by the Clinical Global Impressions (CGI) at 25 weeks [ Time Frame: Baseline-25 weeks ] [ Designated as safety issue: No ]Global psychopathology will be measured with the Clinical Global Impressions (CGI) (Guy 1976) a widely used scale which evaluates illness severity on a 1 to 7 point continuum. Severity of illness ratings on the CGI have reported reliability scores ranging from 0.41-0.66 (Guy 1976)
- Change in Social and Occupational Functioning Scale (SOFAS) as measured at 25 weeks [ Time Frame: Baseline-25 weeks ] [ Designated as safety issue: No ]Life and Work Functional status will be evaluated using the Social and Occupational Functioning Scale (SOFAS), which is derived from the GAF. The GAF is a 100-point single-item scale which measures global functioning of psychiatric patients and is widely utilized in clinical studies involving Seriously Mentally Ill patients (Jones 1995). The reliability of the GAF ranges from 0.62-0.82.
- Treatment satisfaction as measured by the Participant Acceptability and Satisfaction Questionnaire at 25 weeks [ Time Frame: Baseline-25 weeks ] [ Designated as safety issue: No ]Satisfaction will be measured by a seven item inventory taken by the participant.
- Change in schizophrenia and schizoaffective disorder symptom severity scale as measured by the Positive and Negative Syndrome Scale (PANSS) at 25 weeks [ Time Frame: Baseline-25 weeks ] [ Designated as safety issue: No ]The PANSS (Kay, Fiszbein, & Opler 1987) was created to assess both the positive and negative symptoms of schizophrenia such as hallucinations and emotional withdrawal, respectively. The scale rates 30 symptoms on a scale from 1 (absent) to 7 (extreme) and has been shown to limit bias between the assessment of positive and negative symptoms, providing a broad but balanced spectrum of the illness.
- Frequency of health resource use in the past 3 months as measured at 25 weeks [ Time Frame: 13 weeks-25 weeks ] [ Designated as safety issue: No ]The frequency of health resource use will be measured through interview of the participant.
- Change in global psychopathology as measured by the Clinical Global Impressions (CGI) at 12 months [ Time Frame: Baseline-12 months ] [ Designated as safety issue: No ]Global psychopathology will be measured with the Clinical Global Impressions (CGI) (Guy 1976) a widely used scale which evaluates illness severity on a 1 to 7 point continuum. Severity of illness ratings on the CGI have reported reliability scores ranging from 0.41-0.66 (Guy 1976)
- Change in Social and Occupational Functioning Scale (SOFAS) as measured at 12 months [ Time Frame: Baseline-12 months ] [ Designated as safety issue: No ]Life and Work Functional status will be evaluated using the Social and Occupational Functioning Scale (SOFAS), which is derived from the GAF. The GAF is a 100-point single-item scale which measures global functioning of psychiatric patients and is widely utilized in clinical studies involving Seriously Mentally Ill patients (Jones 1995). The reliability of the GAF ranges from 0.62-0.82.
- Treatment satisfaction as measured by the Participant Acceptability and Satisfaction Questionnaire at 12 months [ Time Frame: Baseline-12 months ] [ Designated as safety issue: No ]Satisfaction will be measured by a seven item inventory taken by the participant.
- Change from baseline in days homeless out of the previous 6 months as measured at 12 months [ Time Frame: Baseline-12 months ] [ Designated as safety issue: No ]Subjects will be asked how many days they have been homeless
- Change from baseline in treatment adherence score as measured at 12 months [ Time Frame: Baseline-12 months ] [ Designated as safety issue: No ]A total treatment adherence score will calculated as a proportion of medications taken as reported from the participant, and evidenced by pill counts and documented medication injections.
- Change from baseline in adherence attitude score as measured by the Drug Attitude Inventory (DAI) at 12 months [ Time Frame: Baseline-12 months ] [ Designated as safety issue: No ]Ten item inventory taken by the participant with a Scale Range: 0-10
- Change from baseline in treatment adherence behavior score as measured by the Morisky Medication Rating Scale at 12 months [ Time Frame: Baseline-12 months ] [ Designated as safety issue: No ]Four item inventory taken by participant with Scale Range: 0-4
- Change from baseline in adherence attitude score as measured by the Attitude toward Medication Questionnaire (AMQ) at 12 months [ Time Frame: Baseline-12 weeks ] [ Designated as safety issue: No ]Nineteen item inventory taken by the participant with Scale Range: 0-19
| Estimated Enrollment: | 30 |
| Study Start Date: | June 2010 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: haloperidol decanoate
Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
Drug: haloperidol
Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
Behavioral: Customized Adherence Enhancement
CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Individuals age 18 years old and older with schizophrenia or schizoaffective disorder as confirmed by the Mini International Psychiatric Inventory (MINI).
- Individuals who are currently or have been recently homeless (within the past 12 months) as per the official federal definition of homelessness.
- Known to have medication treatment adherence (20% or more missed medications in past week or past month) problems as identified by the Treatment Routines Questionnaire patient or clinician versions (TRQ-P/TRQ-C).
- Ability to be rated on psychiatric rating scales.
- Willingness to take long-acting injectable medication.
- Currently receiving treatment at a Community Mental Health Clinic (CMHC) or another mental health treatment provider who is able to provide continuity of care during and after study participation.
- Able to provide written, informed consent to study participation.
- Women of child-bearing potential must be utilizing reliable, medically-accepted methods of birth control.
Exclusion Criteria:
- Known resistance or intolerance to haloperidol or haloperidol decanoate.
- Medical contraindication to haloperidol or haloperidol decanoate.
- Individuals on long-acting injectable antipsychotic medication immediately prior to study enrollment.
- Prior or current treatment with clozapine.
- Concurrent medical condition or psychiatric illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial.
- Current substance dependence.
- High risk of harm to self or others.
- Female who is currently pregnant or breastfeeding.
- Individual who is already in permanent and supported housing that includes comprehensive mental health services (e.g. Housing First).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01152697
Locations
| United States, Ohio | |
| University Hosptials | |
| Cleveland, Ohio, United States, 44106 | |
Sponsors and Collaborators
University Hospitals of Cleveland
Case Western Reserve University
Investigators
| Principal Investigator: | Martha Sajatovic, MD | University Hospitals of Cleveland |
More Information
No publications provided
| Responsible Party: | Martha Sajatovic, Professor of Psychiatry, University Hospitals of Cleveland |
| ClinicalTrials.gov Identifier: | NCT01152697 History of Changes |
| Other Study ID Numbers: | Reuter-L1473 |
| Study First Received: | June 24, 2010 |
| Last Updated: | May 1, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University Hospitals of Cleveland:
|
nonadherence noncompliance homeless schizophrenia schizoaffective |
Additional relevant MeSH terms:
|
Psychotic Disorders Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Haloperidol Haloperidol decanoate Antipsychotic Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions |
Central Nervous System Agents Therapeutic Uses Gastrointestinal Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Dopamine Antagonists Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents |
ClinicalTrials.gov processed this record on May 23, 2013